Immix Biopharma (IMMX) Interest Expenses (2021 - 2022)

Immix Biopharma has reported Interest Expenses for 7 years, with the latest figure at $356668.0 in Q1 2026.

• Quarterly Interest Expenses fell 18.3% year-over-year to $356668.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $356668.0 (down 18.3% YoY) and the FY2025 annual result came in at $25.3 million, up 60.43% from the prior year.
• Interest Expenses retreated to $356668.0 in Q1 2026 per IMMX's latest filing, from $377682.0 in the prior quarter.
• Over five years, Interest Expenses peaked at $15.8 million in Q4 2024 and troughed at -$9099.0 in Q4 2022.
• A 5-year average of $2.3 million and a median of $436550.0 in 2025 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2022 and 2023: Interest Expenses plunged 1128.14% in 2022, then surged 83976.92% in 2023.
• Over 5 years, Interest Expenses stood at -$9099.0 in 2022, then soared by 83976.92% to $7.6 million in 2023, then surged by 106.56% to $15.8 million in 2024, then slumped by 97.6% to $377682.0 in 2025, then fell by 5.56% to $356668.0 in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $356668.0, $377682.0, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.